Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Jeffrey John Meyer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5116-5137; OpenAlex author ID A5060529206. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 4 papers · 2022: 7 papers · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 17

  1. Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Early-Onset Pancreatic Cancer: Clinical Outcomes and Toxicity. Co-author DOI 10.1016/j.ijrobp.2022.07.1120↗
  2. A Multi-Institutional Safety and Feasibility Study Exploring the Use of Hydrogel to Create Spatial Separation between the Pancreas and Duodenum in Patients wit… Co-author DOI 10.1016/j.prro.2023.11.011↗
  3. Characterizing Compromised Target Coverage With Hypofractionated Radiation Therapy for Pancreatic Cancer. Last author DOI 10.7759/cureus.66882↗
  4. The Timing of Surgery Following Stereotactic Body Radiation Therapy Impacts Local Control for Borderline Resectable or Locally Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers15041252↗
  5. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients trea… Co-author DOI 10.1002/cam4.4527↗
  6. Efficacy and Safety of Reirradiation with Stereotactic Body Radiation Therapy for Locally Recurrent Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.clon.2021.12.014↗
  7. Location, Location, Location: What Should be Targeted Beyond Gross Disease for Localized Pancreatic Ductal Adenocarcinoma? Proposal of a Standardized Clinical … Co-author DOI 10.1016/j.prro.2022.01.005↗
  8. High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resecta… Co-author DOI 10.21037/jgo-21-513↗
  9. Stereotactic body radiation therapy for the treatment of locally recurrent pancreatic cancer after surgical resection. Co-author DOI 10.21037/jgo-22-38↗
  10. Upfront Chemotherapy Followed by Stereotactic Body Radiation Therapy with or without Surgery in Older Patients with Localized Pancreatic Cancer: A Single Insti… Co-author DOI 10.3390/curroncol29010028↗
  11. Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and s… Co-author DOI 10.3857/roj.2021.01060↗
  12. Geometric Reproducibility of Fiducial Markers and Efficacy of a Patient-Specific Margin Design Using Deep Inspiration Breath Hold for Stereotactic Body Radiati… Co-author DOI 10.1016/j.adro.2021.100655↗
  13. Fiducial-based image-guided SBRT for pancreatic adenocarcinoma: Does inter-and intra-fraction treatment variation warrant adaptive therapy? Co-author DOI 10.1186/s13014-021-01782-w↗
  14. Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy. Co-author DOI 10.1186/s13014-021-01969-1↗
  15. Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemot… Co-author DOI 10.3857/roj.2021.00815↗
  16. Evaluation of a Novel Absorbable Radiopaque Hydrogel in Patients Undergoing Image Guided Radiation Therapy for Borderline Resectable and Locally Advanced Pancr… Co-author DOI 10.1016/j.prro.2020.01.013↗
  17. Dosimetric and motion analysis of margin-intensive therapy by stereotactic ablative radiotherapy for resectable pancreatic cancer. Last author DOI 10.1186/1748-717x-6-146↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Amol Kumar Narang · 16 shared papers, 2020–2026 · strength 2.65
  2. Joseph M. Herman · 15 shared papers, 2020–2026 · strength 2.37
  3. Colin Hill · 13 shared papers, 2021–2026 · strength 2.07
  4. Jin Peng He · 12 shared papers, 2020–2026 · strength 1.89
  5. Shuchi Sehgal · 11 shared papers, 2021–2026 · strength 1.79
  6. Abhinav V. Reddy · 11 shared papers, 2021–2026 · strength 1.79
  7. Lei Zheng · 8 shared papers, 2021–2023 · strength 1.21
  8. Kai Ding · 3 shared papers, 2020–2024 · strength 0.43
  9. Eun Ji Shin · 2 shared papers, 2020–2024 · strength 0.30
  10. S. Han-Oh · 2 shared papers, 2021 · strength 0.28
  11. Ken Kang‐Hsin Wang · 2 shared papers, 2021 · strength 0.28
  12. I‐Chia Liu · 1 shared paper, 2024 · strength 0.28
  13. Ana De Jesus‐Acosta · 2 shared papers, 2022 · strength 0.27
  14. Daniel A. Laheru · 2 shared papers, 2022 · strength 0.27
  15. Amy Hacker‐Prietz · 2 shared papers, 2021–2022 · strength 0.25
  16. Matthew John Weiss · 2 shared papers, 2020–2022 · strength 0.22
  17. Theodore Sunki Hong · 1 shared paper, 2024 · strength 0.20
  18. Kumar Krishnan · 1 shared paper, 2024 · strength 0.20
  19. Eugene Jon Koay · 1 shared paper, 2024 · strength 0.20
  20. Manoop S. Bhutani · 1 shared paper, 2024 · strength 0.20
  21. Timothy A. Lin · 1 shared paper, 2023 · strength 0.18
  22. Atif Zaheer · 1 shared paper, 2022 · strength 0.15
  23. Zhi Cheng · 1 shared paper, 2021 · strength 0.15
  24. Ding Ding · 1 shared paper, 2021 · strength 0.13
  25. Dung Thi Le · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.